Oncolytic adenoviruses can promote immune responses against tumors by expressing and/or displaying tumor-associated antigens. However, the strong immunodominance of viral antigens mask responses against tumor epitopes. In addition, defects in major histocompatibility complex class I antigen presentation pathway such as the downregulation of the transporter-associated with antigen processing (TAP) are frequently associated with immune evasion of tumor cells. To promote the immunogenicity of exogenous epitopes in the context of an oncolytic adenovirus, we have taken advantage of the ER localization of the viral protein E3-19K. We have inserted tumor-associated epitopes after the N-terminal signal sequence for membrane insertion of this protein and flanked them with linkers cleavable by the protease furin to facilitate their TAP-independent presentation. This strategy allowed an enhanced presentation of the exogenous epitopes in TAP-deficient tumor cells in vitro and the generation of higher specific immune responses in vivo that were able to significantly control tumor growth.
INTRODUCTION
Oncolytic adenoviruses have the ability to selectively replicate in tumor cells while sparing normal tissues. In contrast to the idea that the immune system can limit the efficacy of virotherapy, evidence accumulated during the last years suggests that the virus-induced immune activation is critical to achieve antitumor efficacy. 1, 2 Local inflammation of tumor tissue and immunogenic cell death produced by the infection of cancer cells by oncolytic viruses provides suitable conditions for the triggering of antitumor immune responses. Dying cancer cells also release a natural repertoire of tumor-associated antigens (TAAs) that are uptaken and cross-presented by antigen presenting cells (APCs) activating specific antitumor cytotoxic T lymphocytes (CTLs) against numerous epitopes. 3 Moreover, oncolytic adenoviruses have also been shown to induce autophagy, which further facilitates crosspresentation by APCs. 4, 5 The expression or display of TAAs by oncolytic adenoviruses aimed to induce specific antitumor responses represents an attractive vaccination-like approach. Nevertheless, one concern regarding the use of adenovirus-based cancer vaccines is the immunodominance of adenoviral antigens masking immune responses generated against the exogenous antigens. 6, 7 For this reason, it is important to develop new strategies that increase the immunogenicity of the exogenous epitopes in the context of adenoviral vectors.
On the other hand, tumor cells can acquire defects in antigen processing and presentation pathways, leading to evasion from adaptive immune recognition and contributing to the immunosuppressive tumor microenvironment. Loss of different components of major histocompatibility complex (MHC) class I pathway such as the transporter associated to antigen processing (TAP) have been detected in many different tumor types. 8 In this regard, linking tumor-specific epitopes to membrane-translocating peptides is a previously reported strategy that has been used to bypass antigenprocessing steps and promote TAP-independent presentation. 9, 10 Taking advantage of the natural N-terminal signal sequence for membrane insertion of the adenoviral protein E3-19K, we propose to use this protein to drive tumor-associated epitopes directly to the ER. With this aim, MHC class I-restricted epitopes have been incorporated after the E3-19K leader sequence and separated via linkers cleavable by the transgolgi network resident protease furin, that has an important role in the processing of TAP-independent presented epitopes. 11 Furthermore, we have compared this approach to the display of the same epitopes in the capsid of the adenovirus, which involves its processing by the classical MHC class I presentation pathway.
This novel strategy to incorporate exogenous epitopes into oncolytic adenoviruses addresses a key limitation of immunotherapy with oncolytic viruses: the immunodominance of viral epitopes; and attempts to shift the immune response from viral antigens to tumor antigens. In this study we report that the localization of the exogenous epitopes in the E3-19K increases its immunogenicity and induces the generation of potent antitumor CTL responses.
RESULTS AND DISCUSSION
The selected MHC class I-restricted epitopes were the model epitope OVA 257 (SIINFEKL) 12, 13 and the melanoma-associated epitope gp100 25 (KVPRNQDWL), which is a truly tumor-associated self-antigen. 14 Both peptides were incorporated within the HI-loop of the fiber and flanked by flexible linkers (GSGSA) or inserted between the N-terminal signal sequence of E3-19K (MIRYIILGLL-TLASAHG) and the rest of the protein, and separated via furinlinkers (RVKR). Furthermore, several mutants were constructed by deleting the membrane-translocating sequence of the E3-19K protein and additionally by replacing the furin-linkers by nonrelevant sequences (VRVV). The previously described oncolytic adenovirus ICOVIR-15K has been used as a backbone for the construction of all the viruses. 15 ICOVIR-15K contains an E1a mutated in the pRB-binding site and controlled under minimal E2F binding sites to allow for selective replication in a broad range of tumor cells with pRB pathway alterations. 16 ICOVIR-15K also contains the RGDK mutation, which consists of the replacement of the KKTK domain in the fiber shaft with an RGD motif to improve tumor targeting and antitumor activity 15, 17 (Figure 1 ).
To evaluate the processing and presentation of the peptides in vitro we used an antibody that specifically recognizes OVA 257 epitope bound to MHC class I molecules. 18 TAP-deficient B16CAR or TRAMP-C2 cancer cells [19] [20] [21] were infected with the different adenoviruses in the presence or absence of IFN-γ (interferon-γ), which can upregulate the expression of antigen-processing pathway components. H-2K b /OVA 257 complexes were only detected in the surface of cells infected with the adenovirus containing the peptide in the E3-19K protein (Figures 2a and b) . Importantly, ICOVIR-15K-E3OG was able to promote the presentation of this epitope also in the absence of IFN-γ in the TRAMP-C2 model at the same levels as the positive control corresponding to the cells incubated exogenously with OVA 257 peptide ( Figure 2b ). It is worth noting that ICOVIR-15K-HIOG was not able to induce H-2K b /OVA 257 presentation in the presence of IFN-γ, a scenario where no deficiencies in the MHC class I pathway are supposed to occur. Strikingly, in this condition, the location of the epitopes in E3-19K protein provided a marked advantage to the processing and presentation of the exogenous epitope compared with the display on the capsid. To discard that the improved presentation of OVA 257 by ICOVIR-15K-E3OG was related with a limited expression of fiber protein in mouse cells, the expression of both fiber and E3-19K proteins was confirmed by western blot (Supplementary Figure S1 ). In vitro presentation of OVA 257 was also evaluated upon the transduction of the immature dendritic cell line D1 with the different adenoviruses. As observed in TAP-deficient tumor cell lines, the presentation of OVA 257 could only be detected in ICOVIR-15K-E3OG-infected D1 cells ( Figure 2c ). Moreover, the transduction of dendritic cells with this virus promoted a higher activation according to the maturation marker CD83 compared with the cells transduced with ICOVIR-15K or ICOVIR-15K-HIOG (Figure 2e ).
In order to elucidate the mechanisms of this increased presentation in vitro, further presentation studies were performed with mutant viruses in the TAP-competent mastocytoma cell line P815K b . The deletion of the N-terminal signal sequence caused a 50% reduction in the presentation of OVA 257 peptide when compared with the virus containing the signal sequence. Moreover, upon infection with a virus that also has the furinsensitive linkers replaced by furin-resistant linkers, the surface expression of H-2K b /OVA 257 complexes was completely abrogated, evidencing the implication of the TAP-independent presentation pathway ( Figure 2d ). Furthermore, a TAP-defective situation was mimicked in the same cell line by inhibiting the proteasome with lactacystin (LC). Importantly, the presentation of OVA 257 upon the infection of the cells with ICOVIR-15K-E3OG was not affected by this inhibition, demonstrating that OVA 257 processing was not dependent on the classical presentation pathway. However, we found that the inhibition of the proteasome further reduced the presentation of OVA 257 by the signal sequence-deleted adenovirus, suggesting that, in this case, the TAP-dependent pathway was involved. As expected, the treatment of the cells with the vesicular transport inhibitor brefeldin A (BFA), which was the positive control of inhibition, completely abrogated the surface presentation of H-2K b /OVA 257 complexes upon the infection with all viruses (Figure 2c ).
The next step was to study if the improved presentation of the peptides presented in a TAP-independent manner was also translated into the generation of higher specific immune responses in vivo. With this aim, immunocompetent C57BL/6 mice were immunized by the subcutaneous implantation of TAP-deficient tumor cells B16CAR or TRAMP-C2 that had been previously infected in vitro with the different adenoviruses. This approach mimics the oncolytic situation, in which the virus would be inside the TAP-deficient tumor cells. Whereas similar levels of response against the immunodominant viral epitope E1b 192 were generated by all the viruses, significantly higher immune responses against OVA 257 were elicited by ICOVIR-15K-E3OG compared with the other groups in both models, indicating a clear advantage provided by the TAP-independent presentation of the epitope (Figures 3a and b ). For the gp100 25 epitope, this Figure 1 . Schematic representation of the genomes of the different viruses used in this study. ICOVIR-15K contains the modified E1a promoter (including four E2F boxes and one Sp1 box) and the truncate E1A protein to confer selectivity for tumor cells. It also incorporates the motif CDCRGDCFC (RGD-4C) replacing the putative HSG-binding domain, KKTK (RGDK modification). The epitopes OVA 257 and gp100 25 have been incorporated within the HI-loop domain of the fiber and flanked by GS-flexible linkers to generate ICOVIR-15K-HIOG. The same epitopes were inserted after the ER-targeting signal sequence of the E3-19K and flanked by furin-linkers for the construction of ICOVIR-15K-E3OG. Two additional mutant viruses were constructed by deleting the ER-targeting signal sequence (ICOVIR-15K-SSdelE3OG) and by combining this deletion with the replacement of the furin-linkers by furin-resistant linkers (ICOVIR-15K-SSdelE3OGFR).
advantage was also clearly seen in TRAMP-C2 model (Figure 3b ), but not in B16CAR (Figure 3a ). This differential presentation of gp100 25 in these two cell lines could be caused by a higher furin level in TRAMP-C2, since the release of the gp100 25 peptide requires more furin cleavages compared with the OVA 257 epitope. However, this possibility should be further studied. Note that Figures 3c and d show the specific immune responses against OVA 257 and gp100 25 peptides relative to the immune response raised against the adenoviral epitope E1b 192 . As E1b 192 is immunodominant in H-2 b mice and we assume that the response mounted against it would be the highest achievable response. Importantly, specific anti-OVA 257 immune responses almost reached the levels of anti-viral responses in both models (that is, 100%) after the immunization with the virus presenting the epitopes in a TAP-independent manner. This observation provides evidences that the novel location for exogenous epitopes in E3-19K is capable to compensate the virus epitope immunodominance by increasing the immunogenicity of exogenous epitopes.
We next evaluated if these enhanced specific immune responses generated against the exogenous epitopes by ICOVIR-15K-E3OG were able to control tumor growth. Mice were pre-immunized as above and one week later were challenged with subcutaneous melanoma B16CAR-OVA tumors expressing both gp100 and OVA antigens. Immunization of mice with B16CAR cells infected either with the parental virus or with the virus displaying the epitopes in the capsid had no effect on tumor growth compared with the mock vehicle group. However, the immunization with ICOVIR-15K-E3OG-infected B16CAR cells was able to significantly inhibit tumor growth compared with all other groups (Figure 4a ). Despite the initial inhibition of tumor growth provided by this virus, at the end of the study tumors were relapsing. Since one of the mechanisms of tumor escape is the loss of the expression of tumor antigens, 22 we decided to assess the levels of expression of both targeted antigens at the latest time point. Whereas no differences among groups were detected in gp100 expression by quantitative RT-PCR (Figure 4c ), lower levels of OVA expression were found in tumors from mice treated with ICOVIR-15K-E3OG (Figure 4d ). This loss of OVA expression, but not of gp100 expression, suggests that the elicited immune response is mainly directed against the exogenous model antigen OVA, and not to the weakly immunogenic self-antigen gp100. This result highlights the need of identifying more immunogenic and tumorspecific antigens to achieve efficient therapies. Moreover, it is also important to point out that targeting many TAAs may decrease the probabilities of tumor escape by antigen expression loss. In this sense, the strategy proposed here allows the incorporation of a wide range MHC class I-restricted epitopes in tandem, as well as the possibility to combine these epitopes with MHC class IIrestricted epitopes.
Finally, the antitumor activity in a therapeutic setting was tested. Subcutaneous B16CAR-OVA tumors were implanted in mice and when they reached a mean volume of 100 mm 3 were injected intratumorally with the different adenoviruses. Importantly, the only virus that had significant antitumor effect compared with the mock group was ICOVIR-15K-E3OG (Figure 4b ). However, in addition to the fast-growing rate of syngenic cell line-based tumor models, testing our strategy in a therapeutic setting was also limited by the lack of replication of human adenovirus in mouse cells. Therefore, the effect of virus-induced oncolysis, which presumably would further enhance the efficacy of the vaccination, could not be assessed in this experimental model.
Altogether, the results presented here indicate that the immunogenicity of exogenous epitopes in the context of adenovirus-based vectors can be increased by fusing them to E3-19K protein, promoting their TAP-independent ER translocation.
MATERIALS AND METHODS

Cell lines and peptides
Human embryonic kidney 293 and A549 human lung carcinoma cell lines were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The murine prostate adenocarcinoma TRAMP-C2 (H-2 b ) was obtained from Dr NM Greenberg (Baylor College of Medicine, Houston, TX, USA). B16CAR (H-2 b ) murine melanoma cell line was obtained from Dr Philippe Erbs (Transgene, France). B16CAR-OVA cell line was generated by the stable transfection of B16CAR with the plasmid pAcNeoOVA (Addgene plasmid 22533, Cambridge, UK). 23 P815K b (H-2 d transfected with H-2K b ) murine mastocytoma cell line was provided by Dr Daniel López (Instituto de Salud Carlos III, Madrid, Spain). All these cell lines were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal bovine serum (FBS; Invitrogen Carlsbad, CA, USA) and penicillinstreptomycin (PS; Gibco-BRL, Barcelona, Spain) at 37°C and 5% CO 2 . B16CAR were maintained with 0.5 mg ml − 1 hygromycin (Invivogene, San Diego, CA, USA) and B16CAR-OVA also with 0.5 mg ml − 1 G418 (Invivogene, San Diego, CA, USA). The C57BL/6derived immature dendritic cell line D1 ref. 24 was grown in Iscove's modified Dulbecco's medium (IMDM) supplemented with 10% FBS, PS, 1% β-mercaptoethanol, and 20 ng ml − 1 GM-CSF (Nordic Biosite, Stockholm, Sweden). E1b 192 (VNIRNCCY), OVA 257 (SIIN-FEKL) and gp100 25 (KVPRNQDWL) peptides were synthesized by GenScript USA Inc. (Piscataway, NJ, USA) at 95% purity and re-suspended following manufacturer's instructions.
Recombinant adenoviruses ICOVIR-15K has been previously described. 15 All modifications were performed following a protocol adapted from Stanton et al. 25 based on homologous recombination in bacteria using a positive-negative selection with the rpsLNeo cassette. First, the rpsLNeo cassette was amplified by PCR from pJetRpsLNeo, a plasmid containing the rpsLneo positive-negative selection markers cloned into pJet1.2/blunt (Gen-Script, Wheelock House, Hong Kong), using specific oligonucleotides for E3-19K (E319KrpslF: 5′-CATAATCCTAGGTTTACTCACCCTTGCGTCA GCCCACGGTGGC;CTGGTGATGATG and E319KrpslR: 5′-CATTACAGGCT GGCTCCTTAAAATCCACCTTTTGGGTGGTTCAGAAGAACTCGTCA) or the HI-loop domain of the fiber (HIlooprpslF: 5′-CATTACACTAAACGGTAC ACAGGAAACAGGAGACACAACTGGCCTGGTGATGATG and HIlooprpslR: 5′-CAGACCAGTCCCATGAAAATGACATAGAGTATGCACTTGGTCAGAA GAACTCGTCA). The cassettes were inserted in the E3-19K or the HI-loop of pAdZICOVIR15K plasmid. Second, the fragments containing the epitopes and the linkers were generated by PCR using overlapping oligonucleotides. The generated fragments were used to replace the rpsLNeo cassette in both E3-19K and HIloop as corresponded, creating pAdZICOVIR15KHIOG, pAdZICOV-IR15KE3OG, pAdZICOVIR15KSSdelE3OG and pAdZICOVIR15KSS delE3OGFR.
ICOVIR-15K-HIOG, ICOVIR-15K-E3OG, ICOVIR-15K-SSdelE3OG and ICOVIR-15K-SSdelE3OGFR were generated by transfection of the plasmids with calcium phosphate standard protocol in HEK293 cells. All viruses were propagated in A549 cells and purified by cesium chloride gradients following standard protocols. Purified viruses were physically titered by optical density at 260 nm in vp per ml (vp, viral particles) and functionally titered in TU per mL (TU, transducing units) using an anti-hexon staining-based method.
Flow cytometry analysis
Briefly, B16CAR and TRAMP-C2 cells were treated or not with IFN-γ at 200 IU ml − 1 for 24 h at 37°C. Then, were infected at 100 TU per cell with the different adenoviruses for 4 h at 37°C, were washed three times with PBS and incubated overnight in fresh media. D1 cells were transduced with 1000 TU per cell with the different adenoviruses. Alternatively, cells were pulsed overnight with OVA 257 or gp100 25 peptides at 1 μm. Then, cells were trypsinized, washed three times with fluorescence activated cell sorting buffer (PBS, 10% FBS and 0.01% sodium azide), and stained 30 min at 4°C with the antibodies for flow analysis. The presentation of OVA 257 epitope in vitro was evaluated by fluorescent flow cytometry using the PE-labeled mAb 25D1.16 specific for the Kb/OVA 257 complexes. 18 As a maturation marker of D1 cells CD83 was stained with APC-labeled anti CD83 antibody (clone MICHEL-19). APC-labeled rat IgG1 was used as isotype control (clone RTK2071). All the antibodies used were from Biolegend (San Diego, CA, USA). A Gallios (Beckman Coulter, Brea, CA, USA) cytometer was used and 10 000 events were analyzed for each sample. FlowJo v7.6.5 (Tree Star, Inc., San Carlos, CA, USA) software was used for the analysis of the data. For the inhibition experiments, P815K b cells were infected at 200 TU per cell with the different adenoviruses during 4 h at 37°C in the presence or not of LC (Enzo Life Sciences, NY, USA) or BFA (Sigma, St Louis, MO, USA) inhibitors at 10 μm or 10 μg ml − 1 , respectively. Twenty-four hours later presentation of OVA 257 was analyzed as above.
Mice immunization and antitumor activity studies
Six-week-old female C57BL/6 mice were administered subcutaneously in the flanks with 1 × 10 6 B16CAR or TRAMP-C2 cells that had been previously infected or not in vitro with the different viruses at 100 TU per cell during 4 h at 37°C (n = 3-6 animals per group). Seven days later, animals were euthanized and spleens were collected to analyze antigen-specific responses as described below.
To evaluate the antitumor activity in the prophylactic setting, animals were challenged with 1 × 10 6 B16CAR-OVA cells given subcutaneously 7 days after mice immunization (performed as described above). To evaluate the antitumor activity in the therapeutic setting, 1 × 10 6 B16CAR-OVA cells were given subcutaneously and when tumors reached a mean volume of 100 mm 3 they were injected intratumorally with PBS, or with 2 × 10 9 vp per tumor of ICOVIR-15K, ICOVIR-15K-HIOG or ICOVIR-15K-E3OG in a final volume of 25 μl. Tumor progression and morbidity status were monitored three times weekly. Tumor volume was defined by the equation V(mm 3 ) = π/6 × W 2 × L, where TAP-independent epitopes in oncolytic adenoviruses W and L are width and length of the tumor, respectively. The significance of differences in tumor size between treatment groups was assessed by a two-tailed Student's unpaired t-test.
ELISPOT assays CTL-specific responses were evaluated by IFN-γ ELISPOT. 96-well polyvinylidene fluoride membrane ELISPOT (enzyme-linked immunospot) plates (Millipore, Billerica, MA, USA) were treated with 15 μl of 35% ethanol per well for 1 min. Plates were incubated overnight with IFN-γ-specific capture antibody (BD 551309, San Jose, CA, USA). The day after, plates were washed and blocked with complete media. Mice were sacrificed, spleens were collected and splenocytes isolated, and plated at 250 000cells per well. Phytohaemagglutinin (15 ng ml − 1 ) plus ionomycin (250 ng ml − 1 ) were used as positive control and media only as negative control. Peptides were used at a final concentration of 1 μM. Antigens were incubated with the splenocytes for at least 18 h at 37°C and 5% CO 2. Wells were washed and incubated with the secondary biotinilated anti-IFNγ antibody for 2 h (BD 55156, San Jose, CA, USA), washed and then incubated for 1 h with streptavidinalkaline phosphatase (Sigma E2636, St Louis, MO, USA). Plates were washed with PBS and spots were developed using the BCIP/ NBT solution (Sigma B1911, St Louis, MO, USA) until distinct spots emerged. The plate was washed with tap water, left to dry overnight and spots were counted using the AID EliSpot reader classic (ELR07 de AID GmbH, Straßberg, Germany).
Quantitative real-time PCR Total RNA from tumors was extracted using the RNAeasy Plus Mini Kit (Qiagen, Venlo, The Netherlands) and cDNA was obtained after a reverse transcription reaction (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems, Waltham, MA, USA). Realtime PCR of cDNA was done with SYBR Green (Roche Molecular Biochemicals, Basel, Switzerland) and specific primers for mouse gp100 (5′-CCAGCCCATTGCTGCCCACA and 5′-CTGTGTCCTGCCAAG GCGGG), OVA (5′-GCCTGATGAAGTCTCAGGCC and 5′-AAGCAGGCA GAGAGGTGGTA), and the housekeeping gene mouse β-actin (5′-GGGGGTTGAGGTGTTGAG and 5′-GTCTCAAGTCAGTGTACAGGC C). Real-time PCR was run on a LightCycler instrument (Roche Molecular Biochemicals). Forty-three cycles of amplification with denaturation at 95°C for 10 s followed by annealing at 60°C for 20 s and extension at 72°C for 20 s were done after an initial incubation at 95°C for 10 min. The dC t values were calculated after subtracting the mean C t values of β-actin gene from the receptor gene mean C t values.
